| Primary |
| Malignant Melanoma |
74.1% |
| Malignant Melanoma Stage Iii |
10.3% |
| Metastatic Malignant Melanoma |
9.5% |
| Hepatitis C |
1.7% |
| General Symptom |
0.9% |
| Metastatic Neoplasm |
0.9% |
| Neoplasm Malignant |
0.9% |
| Product Used For Unknown Indication |
0.9% |
| Prophylaxis |
0.9% |
|
| Rash |
10.8% |
| Vomiting |
10.8% |
| Malignant Melanoma |
7.7% |
| Pyrexia |
7.7% |
| Weight Decreased |
7.7% |
| Urticaria |
6.2% |
| Convulsion |
4.6% |
| Depression |
4.6% |
| Suicidal Ideation |
4.6% |
| Vision Blurred |
4.6% |
| Chills |
3.1% |
| Death |
3.1% |
| Fatigue |
3.1% |
| Injection Site Necrosis |
3.1% |
| Injection Site Pain |
3.1% |
| Loss Of Consciousness |
3.1% |
| Metastatic Malignant Melanoma |
3.1% |
| Neuropathy Peripheral |
3.1% |
| Neutropenia |
3.1% |
| Rash Generalised |
3.1% |
|
| Secondary |
| Malignant Melanoma |
44.1% |
| Metastatic Malignant Melanoma |
29.4% |
| Melanoma |
8.8% |
| Melanoma |
5.9% |
| Investigation |
5.9% |
| Malignant Melanoma Stage Iii |
2.9% |
| Prophylaxis |
2.9% |
|
| Vomiting |
14.3% |
| Thrombocytopenia |
10.7% |
| Diarrhoea |
7.1% |
| Hypopituitarism |
7.1% |
| Neutrophil Count Decreased |
7.1% |
| Rash |
7.1% |
| Urticaria |
7.1% |
| Alopecia |
3.6% |
| Cellulitis |
3.6% |
| Injection Site Erythema |
3.6% |
| Lacunar Infarction |
3.6% |
| Loss Of Consciousness |
3.6% |
| Malignant Melanoma |
3.6% |
| Mood Altered |
3.6% |
| Pain |
3.6% |
| Product Label Issue |
3.6% |
| Sluggishness |
3.6% |
| Weight Decreased |
3.6% |
|
| Concomitant |
| Metastatic Malignant Melanoma |
100.0% |
|
| Nausea |
50.0% |
| Paraesthesia |
25.0% |
| Vomiting |
25.0% |
|
